[Congressional Record Volume 146, Number 126 (Wednesday, October 11, 2000)]
[Senate]
[Page S10244]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
AMERICAN CANCER SOCIETY'S POSITION ON THE PAIN RELIEF PROMOTION ACT
Mr. WYDEN. Mr. President, on October 4, 2000, I did not correctly
state the American Cancer Society's position on S. 1272, when I stated
that they ``. . . strongly opposed . . . the Pain Relief Promotion
Act.'' Their actual position, taken directly from their recent
statement on the legislation, is as follows:
. . . The American Cancer Society appreciates the
commitment shown by the sponsors of the legislation to
address these issues, but unfortunately is unable to support
this legislation as written . . . Careful analysis of the
House-passed measure and a substitute version of the Senate
bill . . . have serious potential to exacerbate the current
problem of under treatment of pain. While there are
provisions to proactively address pain and symptom
management, the Society maintains that any benefit from such
provisions would not outweigh the potential threat posed by
the changes to CSA. Furthermore, neither section of the bill
comprehensively addresses the needs of providers, patients,
and families for ongoing support and education to counter the
current problem of under-treatment of pain--a problem that
often leads to requests for physician-assisted suicide . . .
Under the Act, all physicians and particularly physicians who
care for those with terminal illnesses will be made
especially vulnerable to having their pain and symptom
management treatment decisions questioned by law enforcement
officials not qualified to judge medical decision-making.
This can result in unnecessary investigation, and further
disincentives to aggressively treat pain.
Unfortunately, `intent' cannot be easily determined,
particularly in the area of medicine where effective dosage
levels for patients may deviate significantly from the norm.
The question of deciding intent should remain in the hands of
those properly trained to make such decisions--the medical
community and state medical boards. The Pain Relief Promotion
Act seeks to hold harmless any physician who treats a
patient's pain even if death occurs, and the measure attempts
to create a `safe harbor' provision in an effort to shield
physicians whose use of federally-controlled drugs
unintentionally hasten or cause death. However, this
provision does not change the fact that the DEA would now
explicitly be charged with overseeing the medical use of
controlled substances, resulting in a negative impact on
cancer pain treatment. . .
The American Cancer Society statement concluded with the following
observation:
The American Cancer Society has engaged in a deliberative
process to evaluate the impact of the Pain Relief Promotion
Act on our Quality of Life goals for all people living with
cancer. Its analysis included a review of existing Society
policies on pain and symptom management and opposition to
physician assisted suicide. We have concluded that as
written, the Pain Relief Promotion Act would ban the use of
federally controlled substances for physician-assisted
suicide at the expense of controlling pain and advancing
symptom management. These issues are both critically
important, but are separate issues. While the Society
strongly opposes all patient deaths stemming from assisted
suicides, we must give heavier weight to the more than 1500
individuals who die of cancer every day in this country--more
than half of whom die in pain unnecessarily. Moreover, the
American Cancer Society believes that the best approach to
help cancer patients and reduce and prevent assisted suicide
is through the adoption of proactive policies and the
provision of resources to prevent and ameliorate pain and
suffering in people with cancer, especially for those at the
end-of-life.
I appreciate this opportunity to clarify the position of the American
Cancer Society on S. 1272.
____________________